About
Nautilus Biotechnology is a life sciences company building the Voyager Platform — a next-generation proteomics instrument that leverages Iterative Mapping to transform how researchers study proteins. Unlike traditional proteomics approaches that are limited in sensitivity and dynamic range, the Voyager Platform quantifies virtually every protein in the proteome at the single-molecule level, offering exceptional accuracy, reproducibility, and ease of interpretation through digital counts. The platform supports both broadscale proteomic analyses — covering the full proteome — and targeted proteoform analyses, revealing how combinations of post-translational modifications function at the single-molecule level. This dual capability enables researchers to uncover hidden biology that genomic or transcriptomic data cannot predict. Key application areas include drug development, where the platform helps identify promising targets by accurately mapping disease-driving proteins and proteoforms; biomarker discovery, enabling tracking of proteomic signatures across disease progression and treatment response; and exploratory research for any lab seeking comprehensive proteome views to understand biological function. Nautilus has established research collaborations with leading institutions such as Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to advance single-molecule proteomics in diseases like Parkinson's. The platform is currently available through an Early Access Program, making it accessible to pioneering research groups who want to be among the first to generate single-molecule proteomic insights. It is designed for scientific researchers, biotech companies, and pharmaceutical organizations seeking to accelerate discovery through superior proteomics data.
Key Features
- Iterative Mapping Technology: Proprietary method that quantifies proteins and proteoforms at the single-molecule level, enabling comprehensive proteome coverage with exceptional detail and reproducibility.
- Broadscale Proteomic Analysis: Capable of quantifying substantively every protein in the proteome in a single experiment, overcoming the limitations of traditional mass spectrometry approaches.
- Targeted Proteoform Analysis: Reveals how combinations of post-translational modifications co-occur on single molecules, providing new insight into proteoform heterogeneity and biological function.
- Digital Count Readouts: Delivers reproducible, easy-to-interpret digital protein counts that accelerate data analysis and downstream biological interpretation.
- Early Access Program: Allows pioneering research groups to gain early access to the Voyager Platform and be among the first to generate single-molecule proteomic insights.
Use Cases
- Drug target identification by accurately quantifying disease-driving proteins and proteoforms across patient samples to reveal promising therapeutic candidates.
- Biomarker discovery for tracking how protein expression changes over disease progression and in response to treatment, enabling the development of diagnostic signatures.
- Neurodegenerative disease research, such as studying tau and alpha-synuclein proteoforms in Alzheimer's and Parkinson's disease at single-molecule resolution.
- Exploratory biology research for labs seeking a comprehensive view of the proteome that cannot be inferred from genome or transcriptome data alone.
- Pharmaceutical R&D workflows requiring reproducible, high-coverage proteomic data to support IND-enabling studies and clinical biomarker programs.
Pros
- Unmatched Single-Molecule Sensitivity: Detects low-abundance proteins and proteoforms that are invisible to conventional proteomics platforms, enabling truly comprehensive biological insights.
- Broad Proteome Coverage: Designed to quantify nearly the entire proteome in a single experiment, eliminating the narrow coverage windows typical of legacy approaches.
- Reproducible and Easy to Interpret: Digital count outputs simplify data analysis and reduce variability, making results straightforward to validate and share across research teams.
- Versatile Use Cases: Supports drug development, biomarker discovery, and exploratory research, making it applicable across a wide range of scientific disciplines.
Cons
- Limited Availability: The platform is currently only accessible through an Early Access Program, meaning most researchers cannot yet use it freely or independently.
- Enterprise-Level Cost: As a next-generation scientific instrument designed for institutional and pharmaceutical use, the platform is likely cost-prohibitive for smaller labs or individual researchers.
- Specialized Use Case: Focused exclusively on proteomics research, limiting its relevance to life sciences applications and not broadly applicable to other fields.
Frequently Asked Questions
What is the Nautilus Voyager Platform?
The Voyager Platform is Nautilus Biotechnology's next-generation proteomics instrument that uses Iterative Mapping technology to quantify proteins and proteoforms at the single-molecule level with broad proteome coverage and high reproducibility.
What is Iterative Mapping?
Iterative Mapping is Nautilus's proprietary technology that enables accurate, sensitive, and reproducible single-molecule quantification of proteins and proteoforms. It works by repeatedly probing protein molecules with affinity reagents to build a unique identity fingerprint for each molecule.
How can I access the Voyager Platform?
The platform is currently available through the Nautilus Iterative Mapping Early Access Program. Researchers and institutions can apply to be among the first to use the platform and generate single-molecule proteomic insights.
What are the primary use cases for the platform?
The platform supports drug development (identifying disease-driving proteins and drug targets), biomarker discovery (tracking proteomic signatures of disease progression), and exploratory research (enabling comprehensive proteome views to understand biological function).
How does the Voyager Platform differ from traditional mass spectrometry-based proteomics?
Unlike traditional mass spectrometry platforms, the Voyager Platform offers single-molecule sensitivity, broader dynamic range, and more comprehensive proteome coverage, along with simplified digital count readouts that don't require deep bioinformatics expertise to interpret.
